Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,242,784
  • Shares Outstanding, K 109,890
  • Annual Sales, $ 13,117 M
  • Annual Income, $ 3,954 M
  • EBIT $ 3,973 M
  • EBITDA $ 4,394 M
  • 60-Month Beta 0.10
  • Price/Sales 5.69
  • Price/Cash Flow 15.62
  • Price/Book 2.53

Options Overview Details

View History
  • Implied Volatility 37.41% ( -1.47%)
  • Historical Volatility 31.47%
  • IV Percentile 96%
  • IV Rank 74.07%
  • IV High 44.40% on 01/10/25
  • IV Low 17.43% on 06/12/24
  • Put/Call Vol Ratio 0.96
  • Today's Volume 542
  • Volume Avg (30-Day) 2,397
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 33,360
  • Open Int (30-Day) 40,605

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 9.58
  • Number of Estimates 9
  • High Estimate 11.51
  • Low Estimate 8.39
  • Prior Year 10.18
  • Growth Rate Est. (year over year) -5.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
666.25 +3.01%
on 01/13/25
743.28 -7.66%
on 01/08/25
-26.07 (-3.66%)
since 12/27/24
3-Month
666.25 +3.01%
on 01/13/25
935.86 -26.66%
on 10/30/24
-242.28 (-26.09%)
since 10/28/24
52-Week
666.25 +3.01%
on 01/13/25
1,211.20 -43.33%
on 08/27/24
-253.72 (-26.99%)
since 01/26/24

Most Recent Stories

More News
Implied Volatility Surging for Regeneron Pharmaceuticals (REGN) Stock Options

Investors in Regeneron Pharmaceuticals, Inc. REGN need to pay close attention to the stock based on moves in the options market lately. That is because the Feb 21, 2025 $965 Call had some of the highest...

REGN : 686.33 (+0.24%)
America’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search

REGN : 686.33 (+0.24%)
What to Expect From Regeneron Pharmaceuticals' Q4 2024 Earnings Report

Regeneron Pharmaceuticals is slated to release its fourth-quarter results next month, and analysts forecast a single-digit dip in its bottom-line figure.

XLV : 146.52 (-0.70%)
$SPX : 6,067.70 (+0.92%)
REGN : 686.33 (+0.24%)
Stocks Settle Mixed Ahead of Wednesday’s US CPI Report

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +0.11%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.52%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.13%. March E-mini S&P...

GOOGL : 195.30 (+1.82%)
AAPL : 238.26 (+3.65%)
DHI : 143.95 (-2.25%)
HEES : 88.05 (-0.32%)
ADM : 50.59 (-3.03%)
$IUXX : 21,463.04 (+1.59%)
URI : 766.95 (-0.38%)
PRGO : 24.79 (-1.43%)
ZNH25 : 109-040 (+0.09%)
KBH : 68.37 (-2.40%)
MSFT : 447.20 (+2.91%)
ESH25 : 6,089.00 (-0.13%)
Regeneron Reports Eylea Sales, Provides Other Pipeline Updates

Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare Conference.Shares of the company moved up in pre-market trading on Jan. 14.Shares of...

BAYRY : 5.6700 (unch)
REGN : 686.33 (+0.24%)
RHHBY : 38.9400 (-0.41%)
SNY : 52.97 (-0.69%)
Stocks Turn Mixed on Some Negative Corporate News

The S&P 500 Index ($SPX ) (SPY ) today is down -0.09%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.21%. March E-mini S&P futures (ESH25...

DHI : 143.95 (-2.25%)
HEES : 88.05 (-0.32%)
ADM : 50.59 (-3.03%)
$IUXX : 21,463.04 (+1.59%)
URI : 766.95 (-0.38%)
PRGO : 24.79 (-1.43%)
ZNH25 : 109-040 (+0.09%)
KBH : 68.37 (-2.40%)
ESH25 : 6,089.00 (-0.13%)
PHM : 115.05 (-2.54%)
LLY : 804.99 (-0.39%)
$DOWI : 44,850.35 (+0.31%)
Stocks and Bonds Climb on a Friendly US PPI Report

The S&P 500 Index ($SPX ) (SPY ) today is up +0.55%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.44%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.81%. March E-mini S&P futures (ESH25...

AMAT : 172.85 (-0.99%)
AVGO : 207.36 (+2.59%)
DHI : 143.95 (-2.25%)
HEES : 88.05 (-0.32%)
ADM : 50.59 (-3.03%)
$IUXX : 21,463.04 (+1.59%)
ASML : 683.35 (-0.99%)
PRGO : 24.79 (-1.43%)
ZNH25 : 109-040 (+0.09%)
KBH : 68.37 (-2.40%)
ESH25 : 6,089.00 (-0.13%)
PHM : 115.05 (-2.54%)
Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 35.6% in the past six months compared with the industry’s decline of 12.3%.The stock has underperformed the sector and the S&P 500 Index during...

BAYRY : 5.6700 (unch)
REGN : 686.33 (+0.24%)
RHHBY : 38.9400 (-0.41%)
AMGN : 280.30 (-0.94%)
SNY : 52.97 (-0.69%)
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference

REGN : 686.33 (+0.24%)
Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial

REGN : 686.33 (+0.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 703.88
2nd Resistance Point 697.09
1st Resistance Point 691.71
Last Price 686.33
1st Support Level 679.54
2nd Support Level 672.75
3rd Support Level 667.37

See More

52-Week High 1,211.20
Fibonacci 61.8% 1,003.03
Fibonacci 50% 938.72
Fibonacci 38.2% 874.42
Last Price 686.33
52-Week Low 666.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar